Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BRD4/CK2-IN-1 is the first potent, orally active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), acting on both BRD4 (IC50: 180 nM) and CK2 (IC50: 230 nM). In triple-negative breast cancer (TNBC), BRD4/CK2-IN-1 induces apoptosis and autophagy-related cell death.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | 10-14 weeks | $ 1,490.00 | |
200 mg | 10-14 weeks | $ 2,232.00 |
Description | BRD4/CK2-IN-1 is the first potent, orally active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), acting on both BRD4 (IC50: 180 nM) and CK2 (IC50: 230 nM). In triple-negative breast cancer (TNBC), BRD4/CK2-IN-1 induces apoptosis and autophagy-related cell death. |
Molecular Weight | 564.03 |
Formula | C29H30ClN5O5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BRD4/CK2-IN-1 inhibitor inhibit